George D. Demetri

High-throughput oncogene mutation profiling in human cancer (2007)

Thomas, Roman K., Baker, Alissa C., Debiasi, Ralph M., Winckler, Wendy, Laframboise, Thomas, Lin, William M., ...

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma

Demetri, George D., Fletcher, Christopher D. M., Mueller, Elisabetta, Sarraf, Pasha, Naujoks, Ryan, Campbell, Natalee, ...

Agonist ligands for the nuclear receptor peroxisome proliferator-activated receptor-γ have been shown to induce terminal differentiation of normal preadipocytes and human liposarcoma cells in vitro....

Adults With Ewing’s Sarcoma/Primitive Neuroectodermal Tumor: Adverse Effect of Older Age and Primary Extraosseous Disease on Outcome

Baldini, Elizabeth H., Demetri, George D., Fletcher, Christopher D. M., Foran, James, Marcus, Karen C., Singer, Samuel

Response to Chemotherapy and Predictors of Survival in Adult Rhabdomyosarcoma

Esnaola, Nestor F., Rubin, Brian P., Baldini, Elizabeth H., Vasudevan, Naren, Demetri, George D., Fletcher, Christopher D. M., ...

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma

Demetri, George D., Fletcher, Christopher D. M., Mueller, Elisabetta, Sarraf, Pasha, Naujoks, Ryan, Campbell, Natalee, ...

Agonist ligands for the nuclear receptor peroxisome proliferator-activated receptor-γ have been shown to induce terminal differentiation of normal preadipocytes and human liposarcoma cells in vitro....

Adults With Ewing’s Sarcoma/Primitive Neuroectodermal Tumor: Adverse Effect of Older Age and Primary Extraosseous Disease on Outcome

Baldini, Elizabeth H., Demetri, George D., Fletcher, Christopher D. M., Foran, James, Marcus, Karen C., Singer, Samuel

Response to Chemotherapy and Predictors of Survival in Adult Rhabdomyosarcoma

Esnaola, Nestor F., Rubin, Brian P., Baldini, Elizabeth H., Vasudevan, Naren, Demetri, George D., Fletcher, Christopher D. M., ...

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas

Li, Danan, Ji, Hongbin, Zaghlul, Sara, McNamara, Kate, Liang, Mei-Chih, Shimamura, Takeshi, ...

Activating EGFR mutations occur in human non–small cell lung cancer (NSCLC), with 5% of human lung squamous cell carcinomas having EGFRvIII mutations and approximately 10%–30% of lung...

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy

Demetri, George D.

Imatinib, a selective, small-molecule tyrosine kinase inhibitor, has life-saving clinical activity in certain cancers, but questions have been raised about the potential for cardiac toxicity through...